Performance analysis of Apimeds Pharmaceuticals US (APUS)
Annual Return
Since May 9, 2025, APUS has had an average annual return of -64.58%, underperforming the benchmark SPY, which returned +27.17% annual.
| 2026 | 2025 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -61.29% | -25.45% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +12.80% | -26.48% | +31.58% | +5.05% | -25.00% | -36.17% | -29.45% | -61.29% | |||||
| 2025 | -20.45% | +0.57% | -1.14% | +5.17% | -2.73% | +23.04% | +32.42% | -43.45% | -25.45% |
Drawdown analysis of Apimeds Pharmaceuticals US (APUS)
The maximum drawdown for the APUS was -83.70%, occurring on Jul 20, 2026. This drawdown has not yet recovered.
The current APUS drawdown is -83.70%.
Since May 9, 2025 APUS has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 2 times
- 20% or more: 4 times
- 10% or more: 5 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -83.70% | Nov 17, 2025 | 166 | Jul 20, 2026 | Ongoing | Ongoing | Ongoing |
| -31.08% | Jul 25, 2025 | 11 | Aug 11, 2025 | 8 | Aug 21, 2025 | 19 |
| -25.91% | May 9, 2025 | 28 | Jun 20, 2025 | 24 | Jul 25, 2025 | 52 |
| -24.67% | Aug 21, 2025 | 28 | Oct 1, 2025 | 23 | Nov 3, 2025 | 51 |
| -18.62% | Nov 4, 2025 | 3 | Nov 7, 2025 | 4 | Nov 13, 2025 | 7 |